{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:31:21Z","timestamp":1790238681845,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1060407"],"award-info":[{"award-number":["1060407"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1094304"],"award-info":[{"award-number":["1094304"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1109626"],"award-info":[{"award-number":["1109626"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the impact of 2 policy changes on quetiapine dispensing in Australia: removal of prior authorisation for prescribing (policy 1: July 2007) and removal of repeat prescriptions for 25\u2010mg quetiapine (policy 2: January 2014).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed an interrupted time series analysis using Pharmaceutical Benefits Scheme claims data (July 2005 to December 2015). We assessed the impact of both policies on monthly quetiapine dispensing (25\u00a0mg and &gt;25\u00a0mg) and the impact of policy change 2 on monthly rates of 25\u2010mg discontinuation and switching from 25\u00a0mg to other quetiapine strengths. We also estimated the impact of both policies on the proportion of people with potentially inappropriate therapy (no evidence of dose escalation) following 25\u2010mg initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following removal of prior authorisation, 25\u2010mg and &gt;25\u2010mg quetiapine dispensing in the Pharmaceutical Benefits Scheme 10% sample increased by 11\/month (95% CI: 2\u201321) and 14\/month (95% CI: 8\u201320), respectively. After removing 25\u2010mg repeats, there was a permanent decrease of 1072 (95% CI 773\u20131371) dispensings and an increase in discontinuation of this strength; 48% of people dispensed the 25\u2010mg strength that discontinued, discontinued quetiapine completely; the remainder continued to use higher quetiapine strengths. We observed minimal switching to other quetiapine strengths. There was no change in inappropriate 25\u2010mg therapy following policy change 1 and a small decrease (79% to 76%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.05) following policy change 2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>More nuanced policies are needed to ensure the appropriate access to 25\u2010mg quetiapine for dose escalation while discouraging use for indications where the evidence of risk and benefit is unclear.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4408","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T01:02:43Z","timestamp":1519866163000},"page":"439-446","source":"Crossref","is-referenced-by-count":9,"title":["The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a policy pendulum using interrupted time series analysis"],"prefix":"10.1002","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-7495","authenticated-orcid":false,"given":"Jonathan","family":"Brett","sequence":"first","affiliation":[{"name":"Medicines Policy Research Unit, Centre for Big Data Research in Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-4997","authenticated-orcid":false,"given":"Andrea","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Medicines Policy Research Unit, Centre for Big Data Research in Health University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Dobbins","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Buckley","sequence":"additional","affiliation":[{"name":"School of Medicine The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie\u2010Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Medicines Policy Research Unit, Centre for Big Data Research in Health University of New South Wales  Sydney New South Wales Australia"},{"name":"Menzies Centre for Health Policy The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60857-0"},{"key":"e_1_2_10_3_1","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont M","year":"2004","journal-title":"Cochrane Libr"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004867417721018"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"e_1_2_10_6_1","unstructured":"Writing Group for Therapeutic Guidelines.Psychotropics V7.2013."},{"key":"e_1_2_10_7_1","unstructured":"Drug Utilisation Subcommittee.DUSC review on the utilisation of antipsychotics. Australian Department of Health; Pharmaceautical Benefits Scheme;2013."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3538"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2015.032"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.12.1443"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11632030-000000000-00000"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-009-9200-0"},{"key":"e_1_2_10_13_1","unstructured":"Pharmaceutical Benefits Advisory Committee.Streamline authority initiative review.2008."},{"issue":"2","key":"e_1_2_10_14_1","first-page":"e52","article-title":"Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid","volume":"20","author":"Seabury SA","year":"2014","journal-title":"Am J Manag Care"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.27.3.w185"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2010.1296"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_10_18_1","unstructured":"World Health Organisation.ACT\/DDD Index 2018.https:\/\/www.whocc.no\/atc_ddd_index\/.2018. Accessed January 2018."},{"key":"e_1_2_10_19_1","unstructured":"Therapeutic Goods Administration.Product and Consumer Medicine Information: Quetiapine.2017. Available from:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm%26amp%3Bt%3D%26amp%3Bq%3Dquetiapine. Accessed June 2017."},{"key":"e_1_2_10_20_1","unstructured":"Australian Government Department of Health (DoH) PBS.Quetiapine. Available from:http:\/\/www.pbs.gov.au\/medicine\/item\/9202H\u20105458G\u20109204K\u20108456C\u20109205L\u20108580N\u20108458E\u20108457D\u20109203J.2017. Accessed June 2017."},{"key":"e_1_2_10_21_1","volume-title":"Time Series Analysis: Forecasting and Control","author":"Box GE","year":"2015"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176350273"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.08.009"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M620"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.n161245"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-9276-13-53"},{"key":"e_1_2_10_27_1","unstructured":"Drug Utilisation Subcommittee.Antipsychotic medicines: 24 month review of quetiapine 25mg. Australian Department of Health; Pharmaceautical Benefits Scheme;2016."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.15.1458"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3609"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2015.07.001"},{"key":"e_1_2_10_31_1","unstructured":"Australian Department of Health.Australian statistics on medicines 2011. Canberra.2013.http:\/\/www.pbs.gov.au\/info\/statistics\/asm\/asm\u20102011. Accessed June 2017."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:06:40Z","timestamp":1695560800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1002\/pds.4408"],"URL":"https:\/\/doi.org\/10.1002\/pds.4408","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]}}}